Every S-1 that Profusa, Inc. (PFSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow PFSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFSA filings page.
Profusa, Inc. is registering 179,272,293 shares of common stock for resale by existing holders. This total includes 150,568,827 purchase shares under a $100,000,000 equity line with Ascent, 20,027,859 shares issuable upon conversion of Ascent Notes, 3,333,333 warrant shares, and 5,342,274 shares issuable upon conversion of Sponsor notes.
Shares outstanding were 4,410,268 as of April 29, 2026, and would be 180,349,228 assuming full conversion of the Ascent and Sponsor notes, meaning very substantial dilution for current holders. Profusa discloses large historical net losses, substantial doubt about its ability to continue as a going concern, heavy reliance on external financing, and multiple Nasdaq listing deficiencies that could lead to delisting if not cured.
Profusa, Inc. has filed a resale registration covering up to 179,272,293 shares of common stock for sale by existing holders. The shares include 150,568,827 purchase shares tied to a $100,000,000 equity line with Ascent, plus conversion and warrant shares from Ascent’s note and warrant financing and a sponsor note.
Profusa will not receive proceeds from stockholder resales but may raise up to $100,000,000 by selling purchase shares to Ascent and up to $1,666,666.50 from cash exercises of Ascent inducement warrants. As of April 24, 2026, 4,410,268 shares were outstanding, so full issuance would be highly dilutive. The company reports large accumulated losses, substantial doubt about its ability to continue as a going concern, heavy reliance on external financing, and Nasdaq listing deficiency notices, while still seeking U.S. regulatory approvals for its biointegrated sensor products.
Profusa, Inc. has filed an amended S-1 registering the issuance of up to 126,500 shares of common stock upon exercise of its Public Warrants and the resale of up to 579,865 shares by selling stockholders. This includes 333,333 Purchase Shares Ascent may buy under a $100,000,000 equity line of credit, where Profusa controls timing and size of draws.
The company expects any net proceeds from ELOC sales to be used mainly to purchase Bitcoin, subject to a $5,000,000 minimum cash balance, and may also receive up to $200,148,875 if 17,404,250 outstanding warrants are exercised in cash. Profusa reports only 1,359,374 shares outstanding as of February 13, 2026 and warns that additional issuances will dilute existing holders.
The filing describes a reverse stock split at a 1‑for‑75 ratio, Nasdaq listing deficiencies on bid price and market value, significant operating losses, and substantial doubt about its ability to continue as a going concern. It also highlights a Mayo Clinic license for oxygen‑related applications, forgiveness of a $1.3 million PPP loan, and an early‑stage biosensor business focused on Lumee Oxygen and Lumee Glucose platforms.
Profusa, Inc. filed Amendment No. 1 to its Form S-1 as an exhibit-only update. The amendment replaces the consent of its independent registered public accounting firm and corrects amounts in the offering expense table, which now totals $387,445 including legal, accounting, printing, transfer agent and regulatory fees.
The filing also summarizes prior 2025 financing arrangements, including senior secured convertible notes with up to $22,222,222 in principal featuring a 10% original issue discount, and an equity line of credit giving Ascent the right to purchase up to $100,000,000 of common stock, both subject to detailed pricing floors and ownership limits.
Profusa, Inc. has filed an S-1 to offer up to 5,102,040 Units and up to 5,102,040 Pre-funded Units, plus 15,306,120 shares of common stock underlying associated Warrants and Pre-funded Warrants. Each Unit includes one common share and two five-year warrants with an assumed exercise price of $2.94 per share.
The best-efforts offering has no minimum, so proceeds could be well below the maximum. At the assumed $2.94 price, Profusa estimates net proceeds of about $14.6 million, with roughly $12.3 million earmarked for working capital and general corporate purposes and $2.3 million to repay a Tasly convertible note.
Profusa develops long-term biointegrated sensors, including its Lumee Oxygen Platform in the EU and a glucose monitoring platform still seeking U.S. approval. The company reports substantial losses, going-concern doubts, and multiple Nasdaq listing deficiency notices, and has relied heavily on an equity line of credit for funding. Recent developments include a Mayo Clinic license agreement for oxygen-measurement know-how and full forgiveness of a $1.3 million PPP loan.